Boston Scientific Corporation (BSX) Expected to Earn Q4 2017 Earnings of $0.33 Per Share

Boston Scientific Corporation (NYSE:BSX) – Investment analysts at Leerink Swann reduced their Q4 2017 earnings per share (EPS) estimates for shares of Boston Scientific in a report released on Wednesday. Leerink Swann analyst D. Antalffy now forecasts that the medical equipment provider will earn $0.33 per share for the quarter, down from their previous forecast of $0.34.

Several other research analysts also recently commented on BSX. Cowen set a $31.00 target price on shares of Boston Scientific and gave the stock a “buy” rating in a research note on Thursday, November 30th. SunTrust Banks set a $33.00 target price on shares of Boston Scientific and gave the stock a “buy” rating in a research note on Monday. Oppenheimer reiterated a “hold” rating on shares of Boston Scientific in a report on Wednesday, November 29th. BMO Capital Markets reiterated a “buy” rating and issued a $31.00 price target on shares of Boston Scientific in a report on Wednesday, November 29th. Finally, BTIG Research upgraded shares of Boston Scientific from a “neutral” rating to a “buy” rating and set a $31.00 price target on the stock in a report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $30.97.

Boston Scientific (BSX) opened at $24.94 on Monday. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. Boston Scientific has a one year low of $20.36 and a one year high of $29.93. The company has a market cap of $34,192.58, a price-to-earnings ratio of 20.41, a P/E/G ratio of 1.92 and a beta of 0.96.

Boston Scientific (NYSE:BSX) last issued its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, hitting the consensus estimate of $0.31. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same period in the previous year, the firm earned $0.27 earnings per share. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis.

Hedge funds have recently made changes to their positions in the company. Valeo Financial Advisors LLC bought a new stake in shares of Boston Scientific during the 3rd quarter valued at $138,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Boston Scientific during the 3rd quarter valued at $139,000. Acrospire Investment Management LLC boosted its holdings in shares of Boston Scientific by 157.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock valued at $141,000 after buying an additional 3,100 shares in the last quarter. Bronfman E.L. Rothschild L.P. boosted its holdings in shares of Boston Scientific by 14.3% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock valued at $160,000 after buying an additional 720 shares in the last quarter. Finally, San Francisco Sentry Investment Group CA bought a new stake in shares of Boston Scientific during the 2nd quarter valued at $191,000. Hedge funds and other institutional investors own 90.57% of the company’s stock.

In other news, EVP Timothy A. Pratt sold 11,061 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $29.24, for a total transaction of $323,423.64. Following the sale, the executive vice president now owns 174,681 shares in the company, valued at approximately $5,107,672.44. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Timothy A. Pratt sold 10,000 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $26.04, for a total transaction of $260,400.00. Following the sale, the executive vice president now owns 154,681 shares in the company, valued at approximately $4,027,893.24. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 424,698 shares of company stock worth $12,273,553. Company insiders own 0.74% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Boston Scientific Corporation (BSX) Expected to Earn Q4 2017 Earnings of $0.33 Per Share” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.com-unik.info/2017/12/06/boston-scientific-corporation-bsx-expected-to-earn-q4-2017-earnings-of-0-33-per-share.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit